For the year ending 2025-12-31, PRLD made $12,140K in revenue. -$99,525K in net income. Net profit margin of -819.81%.
| Income Statement | 2025-12-31 | 2024-12-31 | ||
|---|---|---|---|---|
| Revenue | 12,140 | 7,000 | ||
| Research and development | 94,300 | 117,995 | ||
| General and administrative | 22,406 | 28,719 | ||
| Total operating expenses | 116,706 | 146,714 | ||
| Loss from operations | -104,566 | -139,714 | ||
| Other income, net | 5,068 | 12,541 | ||
| Net loss | -99,498 | -127,173 | ||
| Unrealized (loss) on marketable securities, net of tax | -27 | -188 | ||
| Comprehensive loss | -99,525 | -127,361 | ||
| Basic EPS | -1.29 | -1.68 | ||
| Diluted EPS | -1.29 | -1.68 | ||
| Basic Average Shares | 76,956,194 | 75,805,840 | ||
| Diluted Average Shares | 76,956,194 | 75,805,840 | ||
Prelude Therapeutics Inc (PRLD)
Prelude Therapeutics Inc (PRLD)